News23 seconds ago
Rigel Announces Presentation of Data from Analysis of REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML
Durable remissions observed in patients relapsed or refractory to prior venetoclax-based regimens Data featured in a poster presentation at the European Hematology Association (EHA) 2023 Hybrid...
